Skip to main content
Cancer Biomarkers: Section A of Disease Markers logoLink to Cancer Biomarkers: Section A of Disease Markers
. 2021 May 17;31(1):1–11. doi: 10.3233/CBM-201709

LncRNA testis-specific transcript, Y-linked 15 (TTTY15) promotes proliferation, migration and invasion of colorectal cancer cells via regulating miR-29a-3p/DVL3 axis

Xiao-Ying Zheng a, Ming-Zheng Cao b, Ying Ba c, Yue-Feng Li d,*, Jun-Ling Ye a,*
PMCID: PMC12499998  PMID: 33016900

Abstract

BACKGROUND:

Long non-coding RNA testis-specific transcript, Y-linked 15 (TTTY15) is oncogenic in prostate cancer, however its expression and function in colorectal cancer remain largely unknown.

METHODS:

Paired colorectal cancer samples/normal tissues were collected, and the expression levels of TTTY15, miR-29a-3p and disheveled segment polarity protein 3 (DVL3) were examined by quantitative real-time polymerase chain reaction (qRT-PCR); TTTY15 shRNA and overexpression plasmids were transfected into HT29 and HCT-116 cell lines using lipofectamine reagent, respectively; the proliferation and colony formation were detected by CCK-8 assay and plate colony formation assay; qRT-PCR and Western blot were used to analyze the changes of miR-29a-3p and DVL3; dual-luciferase reporter gene assay was used to determine the regulatory relationships between miR-29a-3p and TTTY15, miR-29a-3p and DVL3.

RESULTS:

TTTY15 was significantly up-regulated in cancerous tissues of colorectal cancer samples, positively correlated with the expression of DVL3, while negatively correlated with the expression of miR-29a-3p. After TTTY15 shRNAs were transfected into colorectal cancer cells, the proliferation and metastasis of cancer cells were significantly inhibited, while TTTY15 overexpression had opposite biological effects. TTTY15 shRNA could reduce the expression of DVL3 on both mRNA and protein levels, and the luciferase activity of TTTY15 sequence was also inhibited by miR-29a-3p. DVL3 was also validated as a target gene of miR-29a-3p, and it could be repressed by miR-29a-3p mimics or TTTY15 shRNA.

CONCLUSION:

TTTY15 is abnormally upregulated in colorectal cancer tissues, and it can modulate the proliferation and metastasis of colorectal cancer cells. It functions as the ceRNA to regulate the expression of DVL3 by sponging miR-29a-3p.

Keywords: LncRNA TTTY15, miR-29a-3p, DVL3, Colorectal cancer

1. Introduction

Colorectal cancer (CRC) is a common malignancy of digestive tract. The morbidity of CRC ranks third among cancers, and the mortality of CRC ranks fifth [1, 2]. At present, the treatment approaches of CRC are limited. The main methods are surgery and chemotherapy, but postoperative recurrence and metastasis occurs in 40%–50% cases [3, 4, 5]. The survival rate and quality of life of patients with CRC are needed to be further improved. Exploring the mechanisms of the carcinogenesis and progression of CRC is important for improving the prognosis of CRC patients.

Long non-coding RNA (lncRNA) is a class of RNA molecules that are more than 200 nucleotides in length but cannot encode proteins. It regulates gene expression at the transcriptional, post-transcriptional, and epigenetic levels, thereby affecting cell differentiation, metabolism, proliferation and apoptosis [6]. In the development of some human cancers, the expression of genes on the Y chromosome plays an important role [7, 8, 9, 10]. LncRNA testis-specific transcript, Y-linked 15 (TTTY15) is located in the AZFa region of the Y chromosome, and a recent study shows that the expression of TTTY15 is up-regulated in prostate cancer tissues, and it can drive the progression of prostate cancer tissues by sponging let-7 [11]. Nevertheless, the expression and function of TTTY15 in CRC are much less explored.

MicroRNA (miRNA) is a kind of non-coding RNA (ncRNA) of about 22 nucleotides in length [12]. Reportedly, the dysregulation of miR-29a-3p is related to the carcinogenesis and progression of diverse cancers. It is down-regulated in liver cancer, and its low expression is associated with the lower survival rate of patients; moreover, overexpression of miR-29a-3p can inhibit the proliferation and migration of liver cancer cells by targeting IGF1R [13]. It is also significantly down-regulated in gastric cancer and its low expression facilitates the proliferation, migration and invasion of cancer cells [14]. There are also some studies reporting the expression, biological function and mechanism of miR-29a-3p in CRC [15, 16], but its upstream and downstream molecular mechanisms still need to be further studied.

Disheveled (DVL), a positive regulator of the Wnt signaling pathway, is located upstream of β-catenin and highly expressed in a variety of tumors [17]. Wnt signaling pathway is the key pathway to maintain stem cell-like characteristics such as stem cell growth and self-renewal. Its abnormal activation or mutation is closely related to tumorigenesis [18, 19]. The carcinogenesis and progression of CRC are accompanied by activation of the Wnt pathway [20, 21]. DVL3 is a member of this family, but the molecular mechanism of DVL3 in CRC is expected to be further explored.

This study mainly explored the expression and function of TTTY15 in CRC, and its regulatory function on miR-29a-3p/DVL3 axis in CRC. This work provides useful clues for the diagnosis and treatment of CRC.

2. Materials and methods

2.1. Tissue specimens

The tumor tissues and normal tissues of 51 male patients who underwent radical resection of CRC at Qinghai University Affiliated Hospital from April 2017 to April 2018 were randomly collected. None of patients received chemotherapy or radiotherapy before surgery. The control group specimens were resected from normal tissues of the same patient (at least 2 cm from the surgical margin), and no cancer cells were found during pathological examination. The collection and use of patient tissue samples were approved by the Qinghai University Affiliated Hospital Ethics Committee. All patients involved gave informed consent. Tissue samples were surgically removed and immediately stored at -196C in liquid nitrogen until use.

2.2. Cell culture

Human CRC cell line (HCT-116, HT29, SW480, SW620, DLD-1 cells) and normal colonic epithelial cell line CCD841 were purchased from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA) and 100 U/ml penicillin, 100 μg/ml streptomycin (Life Technologies, Carlsbad, CA, USA) in a constant temperature incubator at 37C in 5% CO2. The culture solution was changed every 3 d, and the cells were passaged when the bottom of the culture flask was covered with the cells. Cells in the logarithmic growth were selected for subsequent assays.

2.3. Cell transfection

The cells in the logarithmic growth phase were inoculated into a 6-well plate with 2.5 × 105 cells per well and the cells were transfected according to the instructions of the Lipofectamine® 3000 (Invitrogen; ThermoFisherScientific, Inc., Carlsbad, CA, USA). TTTY15 shRNA, TTTY15 overexpression plasmid, miR-29a-3p mimics, miR-29a-3p inhibitor, empty vectors, miRNA control were transfected into cells respectively. After 48 h of culture, RNA was extracted and quantitative real-time polymerase chain reaction (qRT-PCR) was performed to verify the transfection efficiency.

2.4. RNA isolation and qRT-PCR

Total RNA was extracted from tissues and cell lines according to the instructions of TRIzol reagent (Invitrogen, Carlsbad, USA). RNA purity and concentration were measured using the NanoDrop ND-2000 spectrophotometer. With M-MLV Reverse Transcriptase (Thermo Fisher Scientific, Inc., Rockford, IL, USA), 5 μg of total RNA was used to reverse transcribed to cDNA. qRT-PCR was performed on the ABI 7300 Real-time PCR System (Applied Biosystems, Foster City, CA, USA) with SYBR Green PCR Master Mix (Thermo Fisher Scientific, Inc.). The qRT-PCR conditions were as follows: pre-denaturation at 95C for 10 min, 95C for 15 s, 60C for 15 s, 45 cycles, and the fluorescence signal was obtained at 60C. The relative expressions of TTTY15, miR-29a-3p and DVL3 were calculated by the 2-ΔΔCt method using GAPDH and U6 as internal references. Primers were listed in Table 1.

Table 1.

Primers used in this study

Name Primer sequences (5’-3’)
TTTY15 Forward:TCTATGACCTGGAAGC
Reverse:ATCTGATG GAACCCTA
miR-29a-3p Forward:AGCACCAUCUGAAAUCGGUUA
Reverse:GTGCAGGGTCCGAGGT
DVL3 Forward:CCATCACCAGCTCCATCC
Reverse:CTGCTGCGTGTAGTGTGG
GAPDH Forward:ACAACTTTGGTATCGTGGAAGG
Reverse:GCCATCACGCCACAGTTTC
U6 Forward:CTCGCTTCGGCAGCACA
Reverse:AACGCTTCACGAATTTGCGT

2.5. Cell counting kit-8 (CCK-8) assay

The cell proliferation curve was determined using CCK-8 assay. HCT-116 and SW480 cells (3000 cells per well) were seeded in 96-well plates and incubated for 1, 2, 3, and 4 d, respectively. Subsequently, 10 μL of enhanced CCK-8 kit (Beyotime, Beijing, China) was added and the cells were incubated at 37C for 1 h. Then then culture was terminated and the absorbance value (optical density, OD value) of each well was measured at 450 nm on a microplate reader, and the relative OD ratio was used to indicate the cell proliferation.

2.6. Plate colony formation assay

Cells in the logarithmic growth phase were trypsini-zed with 0.25% trypsin and dispersed into single cells and counted. The cell suspension was inoculated separately into dishes containing 3 mL culture solution (1000 cells per dish). Subsequently, the cells were cultured in an environment of 37C, 5% CO2 and saturated humidity for 2 weeks. Subsequently, the cell colony formation rate was calculated and the dishes were photographed. Colony formation rate = number of colony/number of cells inoculated × 100%.

2.7. Transwell assay

Transwell assay was used to detect the migration and invasion, with Transwell chambers (Corning, NY, USA). Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) was used in invasion assay, but not in migration assay. The cells in each group transfected for 48 h were taken, trypsinized, resuspended with serum-free medium, counted and seeded into the upper chamber. RPMI-1640 medium containing 10% FBS was added to the lower chamber. The cells were then cultured for 24 h. After that, the cells that failed to migrate or invade were removed. After the migrated or invaded cells being fixed for 4 minutes with 4% paraformaldehyde and stained with 0.5% crystal violet, the cells were rinsed by the tap water, and the cells were observed under an inverted microscope. Cell counting was performed using five fields of view, and the mean value was taken.

2.8. Flow cytometry

Cellular apoptosis was detected by flow cytometry. Cells in the logarithmic growth phase were washed twice with PBS, fixed in 70% ethanol, and stored at 4C overnight. Then the cells were washed once with PBS, and the cell density was adjusted to 1 × 106 cells/mL. The cells were then stained with Annexin V-FITC staining solution and propidium iodide solution (BD Biosciences, San Jose, CA, USA) and incubated for 15 minutes in the dark at room temperature. Finally, the stained cells were analyzed using a flow cytometer (BD Biosciences, San Jose, CA, USA).

2.9. Dual-luciferase reporter gene assay

Luciferase reporter gene assay was performed using the dual-luciferase reporter assay system (Promega, Madison, WI, USA). The target fragments of wild type TTTY15 and mutant TTTY15 were constructed and integrated into pGL3 vector (Promega, Madison, WI, USA) to construct pGL3-TTTY15-wild type (TTTY15-wt) and pGL3-TTTY15-mutant (TTTY15-mut) reporter vectors. Then TTTY15-wt or TTTY15-mut reporter vector was co-transfected into HT29 cells with miR-29a-3p mimics or control miRNA mimics. After 48 h of transfection, luciferase activity was determined in accordance with the manufacturer’s instructions. The same method was used to construct DVL3-wt and DVL3-mut, and to detect the targeted binding relationship between miR-29a-3p and the 3’UTR of DVL3.

2.10. Western blot

RIPA lysis buffer (Beyotime Biotechnology, Beijing, China) containing PMSF was used to extract the protein from CRC cells. Protein samples were subjected for SDS-PAGE and transferred to the nitrocellulose (NC) membrane (Millipore, Billerica, MA, USA). After being blocked with 5% fat-free milk, the membrane was incubated with primary antibodies anti-DVL3, anti-β-catenin and anti-c-Myc (dilution 1:1000, Cell Signaling Technology) and anti-GAPDH (dilution 1:2000, Santa Cruz) antibody at 4C for 8 h. After being washed, the membrane was incubated with horseradish peroxidase (HRP) conjugated secondary antibody (1:2000, Santa Cruz Biotechnology) for 1 h at room temperature. Ultimately, after Enhanced Chemiluminescence Western Blotting Substrate (Dongguan Biotech, Shandong, China) was added on the NC membranes, the membranes were placed on ChemiDocXRS imaging system to calculate the gray value.

2.11. Statistical analysis

All experiments were performed in triplicate and repeated three times. Data analysis was performed using SPSS18.0 statistical software (SPSS Inc., Chicago, IL, USA). All data were expressed as mean ± SD. Statistical analysis was performed by Student’s t-test. Pearson’s correlation analysis was employed to analyze the correlations among TTTY15, miR-29a-3p and DVL3 expression. P< 0.05 was statistically significant.

3. Result

3.1. TTTY15 was highly expressed in CRC tissues and cell lines

In order to explore the expression of TTTY15 in CRC, qRT-PCR assay was employed to detect TTTY15 expression in CRC tissues, normal tissues and CRC cell lines (HCT-116, HT29, SW480, SW620, DLD-1 cells) and normal colorectal epithelial cell line (CCD841 cells). The results revealed that TTTY15 was significantly up-regulated in CRC tissues and cell lines compared non-cancerous tissues and cells (Fig. 1A and B). To explore the significance of high expression of TTTY15 in CRC, we divided the patients into high-expression and low-expression groups according to the expression level of TTTY15. The results implied that the high expression of TTTY15 was significantly associated with lymph node metastasis in CRC (Table 2).

Figure 1.

Figure 1.

Expression of TTTY15 in CRC tissues and cell lines. A. The qRT-PCR assay was employed to detect the expression of TTTY15 in 51 pairs of CRC tissues and paracancerous tissues. B. qRT-PCR assay was employed to detect the expression of TTTY15 in CRC cell lines (HCT-116, HT29, SW480, SW620, DLD-1 cells) and normal colorectal epithelial cell line CCD841. (Compared with Normal group or CCD841, * indicates p< 0.05, ** indicates p< 0.01, *** indicates p< 0.001).

Table 2.

The correlations between TTTY15 expression and Clinicopathologic factors

Clinicopathologic Patients number TTTY15 expression X2 p
factors (n= 51) Lower (n= 23) Higher (n= 28)
Age 0.126 0.723
60 28 12 16
> 60 23 11 12
Location of the tumor 0.216 0.642
 Colon 24 10 14
 Rectum 27 13 14
Diameter (cm) 0.479 0.489
< 5 25 10 15
5 26 13 13
TNM stage 2.753 0.097
 I–II 44 21 23
 III–IV 7 1 6
Lymphatic metastasis 26.609 < 0.001
 Yes 29 4 25
 No 22 19 3

, p< 0.05.

3.2. TTTY15 enhanced proliferation, migration and invasion of CRC cells and impeded the apoptosis

Next, we overexpressed TTTY15 in HCT-116 cell line and knocked down TTTY15 in HT29 cell line (Fig. 2A). The cell proliferation was examined by CCK-8 assay and plate colony formation assay. The results showed that the proliferation of HCT-116 cells was significantly increased after TTTY15 overexpression, and the proliferation of HT29 cells was decreased after TTTY15 knockdown (Fig. 2B–D). In addition, the migration and invasion were detected by Transwell assay, and the results showed that the migration and invasion of CRC cells were increased after overexpression of TTTY15; consistently, there was also a decrease in the invasion and migration of HT29 cells after knockdown of TTTY15 (Fig. 2E and F). After that, flow cytometry was employed to detect cell apoptosis. The results indicated that the apoptosis of HCT-116 cells was significantly decreased after TTTY15 overexpression, while the apoptosis of HT29 cells was increased after TTTY15 knockdown (Fig. 2G).

Figure 2.

Figure 2.

TTTY15 promotes the proliferation, invasion and migration of CRC cells and inhibits the apoptosis. A. The expression levels of TTTY15 in HCT-116 and HT29 cells after overexpression and knockdown of TTTY15 were detected by qRT-PCR. B–D. CCK-8 assay (B) and plate colony formation assay (C, D) were employed to detect the proliferation of TTTY15 overexpression and knockdown cells. E and F. The Transwell assay was employed to detect the migration and invasion of CRC cells after overexpression and knockdown of TTTY15. Flow cytometry was used to detect CRC cell apoptosis after TTTY15 overexpression and knockdown. (Compared with NC + vector or NC + shRNA, * means indicates p< 0.05, ** indicates p< 0.01, *** indicates p< 0.001).

3.3. TTTY15 directly targeted miR-29a-3p and reduced its expression in CRC

To further explore the downstream molecular mechanisms of TTTY15, we conducted a bioinformatics analysis by querying the LncBase Predicted v.2 database (http://carolina.imis.athena-innovation.gr) and found that there were two potential binding sites between TTTY15 and miR-29a-3p (Fig. 3A). We further verified them by dual-luciferase activity assay with HT29 cells. The results showed that miR-29a-3p mimics decreased the luciferase activity of wild type TTTY15 sequences. However, the effect of miR-29a-3p on mutant TTTY15 sequences was not significant (Fig. 3B). In addition, we analyzed the correlation between TTTY15 expression and miR-29a-3p expression in CRC tissues, and the results showed a significant negative correlation between the them (Fig. 3C, r2= 0.513). Previous studies have reported that miR-29a-3p is low-expressed in CRC, and its low expression can enhance cancer cell proliferation and invasion [15, 16], so we supposed that TTTY15 functioned as the upstream molecule of miR-29a-3p in CRC. In vitro experiments showed that the expression of miR-29a-3p was down-regulated after overexpression of TTTY15, and the expression of miR-29a-3p was up-regulated after knockdown of TTTY15 (Fig. 3D). However, regulating the expression of miR-29a-3p had no significant effect on the expression of TTTY15 (Fig. 3E).

Figure 3.

Figure 3.

TTTY15 can directly bind to miR-29a-3p to promote the progression of CRC. A. It was predicted that there were two potential binding sites between TTTY15 and miR-29a-3p. B. The binding relationship between TTTY15 and miR-29a-3p mimics was verified by luciferase gene reporter assay. C. The expression of TTTY15 and miR-29a-3p in 51 groups of CRC tissues was detected by qRT-PCR, and the results showed that their expressions were negatively correlated. D. qRT-PCR assay was employed to detect the effect of overexpression and knockdown of TTTY15 on miR-29a-3p expression. E. The effect of overexpression and knock-down of miR-29a-3p on the expression of TTTY15 was detected by qRT-PCR assay. (Compared with control group/NC + vector/NC + shRNA, * indicates p< 0.05, ** indicates p< 0.01, *** indicates p< 0.001, and NS indicates p> 0.05).

3.4. miR-29a-3p targeted and down-regulated DVL3 in CRC

Recently, DVL3 was a direct target of the miR-29 family [22]. By querying StarBase database (http://starbase.sysu.edu.cn), it was also found that there was a binding site between miR-29a-3p and the 3’UTR of DVL3 (Fig. 4A). Therefore, we supposed that miR-29a-3p could regulate DVL3 and participate in the development of CRC. As expected, miR-29a-3p mimics decreased the luciferase activity of wild type DVL3 3’UTR, but had no significant effect on mutant DVL3 in HT29 cells, which confirmed the binding relationship (Fig. 4B). Additionally, miR-29a-3p was significantly negatively correlated with DVL3 expression in CRC samples (Fig. 4C, r2= 0.570), and the expression of TTTY15 and the expression of DVL3 showed a significant positive correlation (Fig. 4D, r2= 0.568). Additionally, the expression of DVL3 was significantly decreased after overexpression of miR-29a-3p, whereas the expression of DVL3 was remarkably increased after inhibition of miR-29a-3p; what’s more, DVL3 was increased after overexpression of TTTY15 and decreased after knocking down TTTY15, so as β-catenin and c-Myc (Fig. 4E–L). Collectively, we confirmed that DVL3 and Wnt signaling were modulated by TTTY15/miR-29a-3p axis in CRC.

Figure 4.

Figure 4.

miR-29a-3p targeted and downregulated DVL3 in CRC. A. By querying the Starbase database, it was predicted that there was a potential binding site between miR-29a-3p and the 3’UTR of DVL3. B. The binding relationship between miR-29a-3P and DVL3 was verified by luciferase gene reporter assay. C–D. The expressions of TTTY15, miR-29a-3p and DVL3 in 51 cases of CRC tissues were detected by qRT-PCR, and the correlations between miR-29a-3p and DVL3, TTTY15 and DVL3 were analyzed. E–L. The effects of miR-29a-3p and TTTY15 expression on expression level of DVL3, β-catenin and c-Myc were detected by Western blot. (Compared with control group/NC + vector/NC + shRNA, * indicates p< 0.05, ** indicates p< 0.01, *** indicates p< 0.001, and NS indicates p> 0.05).

3.5. TTTY15 knockdown repressed CRC cell viability, migration, and invasion but induced cell apoptosis via regulating miR-29a-3p

Based on the above findings, we made a hypothesis that there could be a TTTY15/miR-29a-3p/DVL3 axis during CRC progression, so we then constructed TTTY15 knockdown cells and TTTY15 shRNA/miR-29a-3p inhibitor co-transfection cells with HT29 cells. The expression of TTTY15, miR-29a-3p, DVL3, β-catenin and c-Myc in different groups of cells was detected by qRT-PCR and Western blot (Fig. 5A–F). The results of CCK-8 assay and plate colony formation assay revealed that the cell proliferation in TTTY15 shRNA/miR-29a-3p inhibitor group was promoted than that in TTTY15 knockdown group, suggesting miR-29a-3p inhibitor transfection reversed the inhibitory effect on cell proliferation induced by TTTY15 knockdown (Fig. 5G and H). Similarly, the results of Transwell assay implied that the migration and invasion in TTTY15 knockdown group were significantly suppressed than that in TTTY15 shRNA/miR-29a-3p inhibitor group (Fig. 5I and J). The results of flow cytometry analysis showed that miR-29a-3p inhibitor transfection could effectively rescue the apoptosis caused by TTTY15 knockdown (Fig. 5K).

Figure 5.

Figure 5.

TTTY15 knockdown repressed CRC cell viability, migration, and invasion but induced cell apoptosis via regulating miR-29a-3p. A–F. The expressions of TTTY15, miR-29a-3p, DVL3, β-catnin and c-Myc in HT29 cells in sh-TTTY15 group and sh-TTTY15/miR-29a-3p inhibitor group were detected by qRT-PCR and Western blot. G and H. CCK-8 method (G) and plate colony formation assay (H) were adopted to detect the proliferation of the cells in each group. I and J. The migration (I) and invasion (J) of cells in each group were detected by Transwell assay. K. Flow cytometry was used to detect the apoptosis of HT29 cells in each group. (Compared with NC, * indicates p< 0.05, ** indicates p< 0.01, *** indicates p< 0.001).

4. Discussion

CRC is a common malignancy. Because early symptoms are not obvious, a large number of patients have metastatic disease when they are diagnosed and lose the opportunity for surgical treatment. The main therapeutic methods for patients with metastatic CRC are chemotherapy, and molecular targeting therapy, but the therapeutic effect is still not satisfactory [23, 24]. Exploring the molecular mechanism of CRC and finding feasible molecular therapeutic targets are important for improving patient survival.

Male and female have different susceptibility to different cancers, and their clinical outcomes and prognosis are different. Y chromosome has a specific effect on male’s development, physiology and disease [25]. It has been reported that the morbidity of CRC in males is significantly higher than that of females, which is associated with higher levels of estrogen in females [26]. Nonetheless, the impact of changes in gene expression on the Y chromosome on the development of CRC remains largely unknown. TTTY15 is located on the Y chromosome. It has been reported that the expression of TTTY15 is up-regulated in myocardial infarction; down-regulation of TTTY15 expression can inhibit hypoxia-induced cardiomyocyte apoptosis [27]. It has also been reported that the expression of TTTY15 is closely related to the carcinogenesis of prostate cancer: it can be fused with USP9Y, and TTTY15-USP9Y fusion is confirmed as a biomarker for early detection of prostate cancer [28]; TTTY15 is up-regulated in PC tissues, and down-regulation of its expression can inhibit the development of tumors [11]. Our study, for the first time, explored the expression and role of TTTY15 in CRC, and confirmed its oncogenic effect. To some extent, the gender differences in CRC are explained, providing a new therapeutic target for the treatment of this disease.

Accumulating reports imply that multiple miRNAs are dysregulated in CRC and function as a tumor suppressors or oncogenic factors. For instance, miR-296 is down-regulated in CRC tissues and cells, and its low expression can enhance the invasion and migration of CRC cells, and miR-296 can target S100A4 to inhibit epithelial-mesenchymal transition (EMT) of CRC cells [29]; miR-18b expression is remarkably increased in CRC tissues, and its overexpression promotes cancer cell proliferation by facilitating cell cycle progression by targeting CDKN2B [30]. In recent years, several studies have found that lncRNAs can regulate miRNA expression levels by sponging it and thus affect tumor progression [31, 32]. To explore the downstream molecular mechanism of TTTY15 in CRC, we identified the binding relationship between TTTY15 and miR-29a-3p. It should be noted that the role of miR-29a-3p in CRC has also been reported. Down-regulation of miR-29a-3p can promote the invasion and migration of CRC cells by regulating the expression of CDC42BPA [16]. We observed that in CRC tissues, the expression of TTTY15 and miR-29a-3p was notably negatively correlated, and it was found that the expression of miR-29a-3p was significantly increased after knocking down TTTY15; the expression of miR-29a-3p was significantly decreased after overexpression of TTTY15. These data not only explained the mechanism by which TTTY15 participated in CRC progression, but also helped clarify the reason of dysregulation of miR-29a-3p in CRC.

Additionally, previous studies have reported that in the osteoarthritis, the miR-29 family can negatively regulate the signaling pathways of Wnt, Smad, and NF-κB signaling, thereby affecting the progression of the disease, while DVL3, FZD3, FZD5, FRAT2, and CK2A2 have been verified to be the direct targets of the miR-29 family [22]. The activation of Wnt signaling pathway is involved in the development of CRC, and after taking the above findings into consideration, we made a hypothesis that there may be TTTY15/miR-29a-3p/DVL3 axis in CRC. In this work, luciferase assay was employed to verify the binding relationship between miR-29a-3p and the 3’UTR of DVL3. Furthermore, the effect of changes in the expression of TTTY15 and miR-29a-3p on the expression of DVL3 was further examined by rescue experiments, and it was confirmed that the transfection of miR-29a-3p mimics decreased the increase of proliferation, migration and invasion of cancer cells caused by overexpression of TTTY15. The above results confirmed the existence of the TTTY15/miR-29a-3p/DVL3 axis in CRC.

5. Conclusion

In summary, TTTY15 expression is significantly up-regulated in CRC, and can enhance DVL3 expression via regulating miR-29a-3p and facilitate the development of CRC.The results of this study further deepen the understanding of the molecular mechanisms of CRC and provide new clues for its treatment.

Conflict of interest

The authors declare that they have no competing interest.

References

  • [1]. Siegel R., Miller K. and Jemal A., Cancer statistics, Ca Cancer J Clin 66 (2016), 7–30. [DOI] [PubMed] [Google Scholar]
  • [2]. Chen W., Zheng R., Zhang S., Zeng H., Xia C., Zuo T., Yang Z., Zou X. and He J., Cancer incidence and mortality in China, Cancer Lett 401 (2017), 63–71. [DOI] [PubMed] [Google Scholar]
  • [3]. Zafar S., Malin J., Grambow S., Abbott D., Kolimaga J., Zullig L., Weeks J., Ayanian J., Kahn K., Ganz P. et al., Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study, Cancer 119 (2013), 854–862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [4]. Altomare D., Di L., Porcelli F., Trizio L., Travaglio E., Tutino M., Dragonieri S., Memeo V. and de Gennaro G., Exhaled volatile organic compounds identify patients with colorectal cancer, Br J Surg 144 (2013), 144–150. [DOI] [PubMed] [Google Scholar]
  • [5]. Jianping S., Liqiang W., Yajing H., Wansong C., Hong L., Min Z., Liu D. and You-Nian L., Dual roles of protein as a template and a sulfur provider: A general approach to metal sulfides for efficient photothermal therapy of cancer, Small 14 (2018), 1702529. [DOI] [PubMed] [Google Scholar]
  • [6]. Dhamija S. and Diedericha S., From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis, Int J Cancer 139 (2016), 269–280. [DOI] [PubMed] [Google Scholar]
  • [7]. Wright D., Day F., Kerrison N., Zink F., Cardona A., Sulem P., Thompson D., Sigurjonsdottir S., Gudbjartsson F., Helgason A. et al., Genetic variants associated with mosaic Y chromosome loss highlight cell cycle genes and overlap with cancer susceptibility, Nat Genet 49 (2017), 674–679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8]. Kido T. and Lau Y.F., Roles of the Y chromosome genes in human cancers, Asian J Androl 17 (2015), 373–380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9]. Patel R., Khalifa A., Isali I. and Shukla S., Prostate cancer susceptibility and growth linked to Y chromosome genes, Front Biosci 10 (2018), 423–436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10]. Wallrapp C., Hähnel S., Boeck W., Soder A., Mincheva A., Lichter P., Leder G., Gansauge F., Sorio C., Scarpa A. et al., Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis, Int J Cancer 91 (2001), 340–344. [DOI] [PubMed] [Google Scholar]
  • [11]. Xiao G., Yao J., Kong D., Ye C., Chen R., Li L., Zeng T., Wang L., Zhang W., Shi X. et al., The Long Noncoding RNA TTTY15, Which Is Located on the Y Chromosome, Promotes Prostate Cancer Progression by Sponging let-7, Eur Urol 76 (2019), 315–326. [DOI] [PubMed] [Google Scholar]
  • [12]. Vishnoi A. and Rani S., MiRNA Biogenesis and Regulation of Diseases: An Overview, Methods Mol Biol 1509 (2017), 1–10. [DOI] [PubMed] [Google Scholar]
  • [13]. Wang X., Liu S., Cao L., Zhang T., Yue D., Wang L., Ping Y., He Q., Zhang C., Wang M. et al., miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma, Oncotarget 8 (2017), 86592–86603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14]. Zhao Z., Wang L., Song W., Cui H., Chen G., Qiao F., Hu J., Zhou R. and Fan H., Reduced miR-29a-3p expression is linked to the cell proliferation and cell migration in gastric cancer, World J Surg Oncol 13 (2015), 101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [15]. Kara M., Yumrutas O., Ozcan O., Celik O., Bozgeyik E., Bozgeyik I. and Tasdemir S., Differential expressions of cancer-associated genes and their regulatory miRNAs in colorectal carcinoma, Gene 567 (2015), 81–86. [DOI] [PubMed] [Google Scholar]
  • [16]. He P., Yip W., Chai B., Chai B., Jabar M., Dusa N., Mohtarrudin N. and Seow H., Inhibition of cell migration and invasion by miR-29a-3p in a colorectal cancer cell line through suppression of CDC42BPA mRNA expression, Oncol Rep 38 (2017), 3554–3566. [DOI] [PubMed] [Google Scholar]
  • [17]. Huang S., Chen J., Tian R., Wang J., Xie C., Gao H., Shan Y., Hong J., Zhang Z., Xu M. et al., Down-regulation of dishevelled-2 inhibits cell proliferation and invasion in hepatoblastoma, Pediatr Blood Cancer 65 (2018), e27032. [DOI] [PubMed] [Google Scholar]
  • [18]. Pai V., Hsu C., Chan T., Liao W., Chuu C., Chen W., Li C., Lin C., Huang S., Chen L. et al., ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-β-catenin signaling, Oncogene 38 (2019), 1340–1353. [DOI] [PubMed] [Google Scholar]
  • [19]. Zou Y., Xie C., Yang S. and Xiong J., AMPK activators suppress breast cancer cell growth by inhibiting DVL3-facilitated Wnt/β-catenin signaling pathway activity, Mol Med Rep 15 (2017), 899–907. [DOI] [PubMed] [Google Scholar]
  • [20]. Basu S., Haase G. and Ben-Zeev A., Wnt signaling in cancer stem cells and colon cancer metastasis, F1000Res 5 (2016), pii: F1000 Faculty Rev-699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21]. Schatoff E., Leach B. and Dow L., Wnt Signaling and Colorectal Cancer, Curr Colorectal Cancer Rep 13 (2017), 101–110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [22]. Le L., Swingler T., Crowe N., Vincent T., Barter M., Donell S., Delany A., Dalmay T., Young D. and Clark I., The microRNA-29 family in cartilage homeostasis and osteoarthritis, J Mol Med (Berl) 94 (2016), 583–596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23]. Zafar S., Malin J., Grambow S., Abbott D., Kolimaga J., Zullig L., Weeks J., Ayanian J., Kahn K., Ganz P. et al., Cancer Care Outcomes Research & Surveillance CanCORS Consortium. Chemotherapy use and patient treatment preferences in advanced colorectal cancer: A prospective cohort study, Cancer 119 (2013), 854–862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24]. Finnberg N., Gokare P. and El-Deiry W., Novel and Emerging Targeted Therapies of Colorectal Cancer, Curr Clin Pharmacol 10 (2015), 279–298. [DOI] [PubMed] [Google Scholar]
  • [25]. Wright D., Day F., Kerrison N., Zink F., Cardona A., Sulem P., Thompson D., Sigurjonsdottir S., Gudbjartsson D., Helgason A. et al., Genetic variants associated with mosaic Y chromosome loss highlight cell cycle genes and overlap with cancer susceptibility, Nat Genet 49 (2017), 674–679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26]. Foster P., Oestrogen and colorectal cancer: Mechanisms and controversies, Int J Colorectal Dis 28 (2013), 737–749. [DOI] [PubMed] [Google Scholar]
  • [27]. Huang S., Tao W., Guo Z., Cao J. and Huang X., Suppression of long noncoding RNA TTTY15 attenuates hypoxia-induced cardiomyocytes injury by targeting miR-455-5p, Gene 701 (2019), 1–8. [DOI] [PubMed] [Google Scholar]
  • [28]. Zhu Y., Ren S., Jing T., Cai X., Liu Y., Wang F., Zhang W., Shi X., Chen R., Shen J. et al., Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome, Urol Oncol 384 (2015), e9–e20. [DOI] [PubMed] [Google Scholar]
  • [29]. He Z., Yu L., Luo S., Li M., Li J., Li Q., Sun Y. and Wang C., miR-296 inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4, BMC Cancer 17 (2017), 140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30]. Li Y., Chen M., Liu J., Li L., Yang X., Zhao J., Wu M. and Ye M., Upregulation of MicroRNA 18b Contributes to the Development of Colorectal Cancer by Inhibiting CDKN2B, Mol Cell Biol 37 (2017), e00391–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [31]. Li X., Deng S., Zhu S., Jin Y., Cui S., Chen J., Xiang C., Li Q., He C., Zhao S., et al., Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by dere-pressing the miR-3923/KRAS pathway, Oncotarget 7 (2016), 6000–6014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [32]. Wei W., Liu Y., Lu Y., Yang B. and Tang L., LncRNA XIST Promotes Pancreatic Cancer Proliferation Through miR-133a/EGFR, J Cell Biochem 118 (2017), 3349–3358. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Biomarkers: Section A of Disease Markers are provided here courtesy of SAGE Publications

RESOURCES